Avalo Therapeutics, Inc.

Stage 4 · Declining · week 1⚠ 3→4 today

As of Oct 22, 2026, Avalo Therapeutics is in Stage 4, the downtrend phase, now in its first week (since Oct 22, 2026). It closed at $7.45, 67.4% below its 52-week high and below its 200-day average, which is falling.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. More about the company

$7.45

-31.71% today

$400M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is AVTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 33w

S4 14w

S2 21w

S3 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 33w → S1 12w → S4 6w → S3 7w → S4 5w → S1 1w → S2 8w → S4 14w → S1 1w → S4 14w → S1 6w → S2 21w → S3 14w → S2 5w → S3 1w → S4 1w → S2 13w → S3 4w → S4 1w current

Total tracked: 166 weeks across 19 stage runs.

AVTX among Biotechnology380th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…380	AVTXAvalo Therapeutics, Inc.	Stage 4 · wk 1	20	−51.3%

vs 52W High

-67.4%

$7.45 lo$22.87 hi

67.4% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 1

1w13w26w

Week 1, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-54.4%

200 DMA: $16.32 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

25.82x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-51.3%

-59.6%

-49.5%

YTD

-56.2%

-57.3%

Scan Membership

Breakout Watch

Latest: 2024-11-01

7 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S43→4

Wk 1 · Vol 25.82x

2026-10-21S3

Wk 4 · Vol 0.87x

2026-10-20S3

Wk 4 · Vol 1.88x

2026-10-19S3

Wk 4 · Vol 2.31x

2026-10-16S3

Wk 4 · Vol 1.02x

2026-10-15S3

Wk 4 · Vol 0.98x

2026-10-14S3

Wk 3 · Vol 1.30x

2026-10-13S3

Wk 3 · Vol 1.78x

2026-10-12S3

Wk 3 · Vol 0.54x

2026-10-09S3

Wk 3 · Vol 0.69x

2026-10-08S3

Wk 3 · Vol 1.05x

2026-10-07S3

Wk 2 · Vol 0.76x

Moving averages & range

50 DMA

$16.28

200 DMA

$16.32

52W High

$22.87

52W Low

$7.45

5D Low

$7.45

Resistance levels (recent highs)

20d High

$15.58

60d High

$20.75

120d High

$22.87

250d High

$22.87

Next resistance

+109.1%

to 20d High

ROE

-36.3%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.9

Avalo Therapeutics: quick answers

What stage is Avalo Therapeutics in?

As of Oct 22, 2026, Avalo Therapeutics (AVTX) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 22, 2026 and is in its first week there. What the four stages mean

Is Avalo Therapeutics in an uptrend?

No. Avalo Therapeutics is in a Stage 4 downtrend. It trades 54.4% below its 200-day average, which is falling.

How far is Avalo Therapeutics from its 52-week high?

Avalo Therapeutics closed at $7.45 on Oct 22, 2026, 67.4% below its 52-week high of $22.87. Its 52-week low is $7.45.

How has Avalo Therapeutics performed over the past year?

As of Oct 22, 2026, Avalo Therapeutics is down 57.3% over the past year and down 56.2% so far in 2026.

Which sector and industry is Avalo Therapeutics in?

Avalo Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.